Nemaura Medical Announces Participation at HLTH 2023, Las Vegas
12 Septiembre 2023 - 8:26AM
Nemaura Medical, Inc.(NASDAQ: NMRD) (“Nemaura” or the “Company”), a
medical technology company focused on developing and
commercialising non-invasive wearable diagnostic devices and
supporting diabetes management and personalized lifestyle coaching
programs, today announced it will be participating at the HLTH 2023
conference, in Las Vegas, in October.
The Company’s attendance is in response to
several enquiries from existing diabetes and metabolic health
program providers, to integrate their daily wear Continuous Glucose
Monitor (CGM) into existing diabetes care, metabolic health, and
weight-loss programs.
The Company believes that its proprietary
technology can serve as a powerful complement to program providers,
empowering users with access to personalized data, insights and
guidance based on their body’s response to glucose intake. This is
expected to allow users to be able to have conversations with their
existing program provider on a broad range of health and
weight-loss topics, for example patients can ask for tailored meal
plans, recipes, exercise routines, stress management techniques,
and motivational insights.
To support third parties, the Company has made
modifications to its architecture to enable sensor integration with
other digital programs. The daily use sensor represents a low-cost
addition to providers’ program costs whilst empowering users in a
way that is not currently possible using invasive sensors due to
the associated high costs. This strategy is expected to allow
Nemaura to scale its commercialisation programs rapidly and
cost-efficiently.
In the United States alone, there are over 1,500
diabetes management programs and a multitude of digital programs
that aim to improve metabolic health and help reduce weight as part
of lifestyle interventions. According to the Centers for Disease
Control and Prevention there are 96 million people over the age of
18 in the USA with pre-diabetes, and over 28 million adults with
diabetes.
Attendees and prospective licensees will be able
to see how the sensor augments user experience, and the potential
it provides for enhanced engagement and sustained benefits from
their existing programs.
About HLTH 2023
HLTH 2023 is a leading forum for consumer health
and wellness brands focusing on wearables, metabolic health,
fitness, nutrition and longevity. The conference attracts over
10,000 attendees, including 2,500+ CEO’s from insurance companies,
self-insured employers and health providers. The conference runs
from October 8th through to October 11th 2023.
About Nemaura Medical,
Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercialising non-invasive wearable
diagnostic devices. The Company is currently also commercialising
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and prediabetes to better manage, reverse, and
prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. Food
and Drug Administration (the “FDA”). proBEAT™ combines non-invasive
glucose data processed using artificial intelligence as part of a
lifestyle program that is being refined for commercial launch.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit www.NemauraMedical.com.
Cautionary Statement Regarding Forward-Looking
Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the U.S., risks related to regulatory status
and the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura’s and its partners’ ability to develop, market and sell
proBEAT™, the availability of substantial additional equity or debt
capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
both proBEAT™ digital health, and sugarBEAT®. There can be no
assurance that the Company will be able to reach a part of or any
of the global market for CGM with its products/services. The FDA
reserves the right to re-evaluate its decision that proBEAT™
qualifies as a general wellness product should it become aware of
any issues such as skin irritation or other adverse events from the
device, as well as any misuse impacting patient safety, and any
other reason as the FDA may see fit at its discretion to determine
the product does not fit the definition of a general wellness
product. These and other risks and uncertainties are identified and
described in more detail in Nemaura’s filings with the United
States Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the most recently
completed fiscal year, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K, as the same may be amended from time
to time. Nemaura undertakes no obligation to publicly update or
revise any forward-looking statements.
Investor Relations:
IR@NemauraMedical.Com
Nemaura Medical (NASDAQ:NMRD)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Nemaura Medical (NASDAQ:NMRD)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024